A Leap from TACE to TACE Potentiated by Immune Response Modulation and Angiogenesis Inhibition for Patients with Intermediate-Stage Hepatocellular Carcinoma: LEAP-012 Phase 3 Randomized Control Trial Protocol.

Nicholas Fidelman

Journal: Cardiovascular and interventional radiology 2022;45(4):413-414

PMID: 34853874

Abstract

Address: Radiology and Biomedical Imaging, University of California San Francisco, 505 Parnassus Avenue, Room M-361, San Francisco, CA, 94143, US. [email protected].

DOI: 10.1007/s00270-021-03010-0

Link outs

Free resources

Medical:

https://medlineplus.gov/livercancer.html

Miscellaneous:

https://assays.cancer.gov/CPTAC-1561

Subscription / membership required

Full Text Sources:

https://dx.doi.org/10.1007/s00270-021-03010-0

MeSH Terms: Humans, Carcinoma, Hepatocellular, Chemoembolization, Therapeutic, Clinical Trials, Phase III as Topic, Immunity, Liver Neoplasms, Randomized Controlled Trials as Topic, Sorafenib, Treatment Outcome, Clinical Trial Protocols as Topic